A database of FDA approved therapeutic peptides and proteins
| This page displays user query in tabular form. |
Th1163 details |
| Primary information | |
|---|---|
| ID | 1682 |
| ThPP ID | Th1163 |
| Therapeutic Peptide/Protein Name | Ancestim |
| Sequence | NA view full sequnce in fasta |
| Functional Classification | Ib |
| Molecular Weight | 18500 |
| Chemical Formula | NA |
| Isoelectric Point | NA |
| Hydrophobicity | NA |
| Melting Point (℃) | NA |
| Half Life | NA |
| Description | Ancestim is a recombinant methionyl human stem cell factor, branded by Amgen as StemGen. It was developed by Amgen and sold to Biovitrium, now Swedish Orphan Biovitrum, in December, 2008. It is a 166 amino acid protein produced by E. coli bacteria into which a gene has been inserted for soluble human stem cell factor. It has a monomeric molecular weight of approximately 18,500 daltons and normally exists as a noncovalently associated dimer. The protein has an amino acid sequence that is identical to the natural sequence predicted from human DNA sequence analysis, except for the addition of an N-terminal methionine retained after expression in E. coli. Because Ancestim is produced in E. coli, it is nonglycosylated. Ancestim is supplied as a sterile, white, preservative-free, lyophilised powder for reconstitution and administration as a subcutaneous (SC) injection and is indicated for use in combination with filgrastim for mobilizing peripheral hematopoietic stem cells for later transplanation in certain cancer patients |
| Indication/Disease | Indicated for use in combination with filgrastim for mobilizing peripheral hematopoietic stem cells for later transplanation in certain cancer patients |
| Pharmacodynamics | NA |
| Mechanism of Action | Recombinant human stem cell factor |
| Toxicity | NA |
| Metabolism | When radiolabelled ancestim was administered to rats, 90% of the radioactivity was excreted in the urine. Ancestim was not quantifiable in rat urine using Enzyme-Linked Immunosorbent Assay (ELISA), indicating degradation to lower molecular weight products prior to excretion. |
| Absorption | 35-41 hr |
| Volume of Distribution | NA |
| Clearance | Apparent clearance (CL/F) is approximately 35 to 40 mL/hour/kg. |
| Categories | NA |
| Patents Number | NA |
| Date of Issue | NA |
| Date of Expiry | NA |
| Drug Interaction | NA |
| Target | NA |
| Information of corresponding available drug in the market | |
| Brand Name | Stemgen |
| Company | Biovitrum Ab (publ) |
| Brand Discription | Ancestim/Water |
| Prescribed for | indicated for use in combination with NEUPOGEN® (filgrastim) in the setting of autologous peripheral blood progenitor cell (PBPC) transplantation for patients at risk of poor PBPC mobilisation to increase the number of PBPC collected in the apheresis harvest, thereby increasing the proportion of patients reaching a PBPC target for transplantation. |
| Chemical Name | NA |
| Formulation | Reconstitute with 1.2 mL sterlie water for injection to yield a concentration of 1.5 mg/mL with a withdrawable volume of 1 mL. Compatibility with saline or other diluents is unknown. During reconstitution, the vial contents may be gently swirled to avoid foaming during dissolution. Avoid excess or vigorous agitation |
| Physcial Appearance | NA |
| Route of Administration | Subcutaneous |
| Recommended Dosage | 20 mcg/kg/day SC |
| Contraindication | It is contraindicated in patients with known hypersensitivity to E coli-derived proteins, ancestim or any component of the product; increased risk of systemic allergic reactions (greater incidence and severity) when STEMGEN® was administered by the IV route |
| Side Effects | Injection site reactions (92%); Paresthesia (29%); Respiratory symptoms (28%); Distant skin reactions (21%);Nausea (16%); Headache (13%); Dizziness (12%); Tachycardia (8%) |
| Useful Link | http://reference.medscape.com/drug/stemgen-ancestim-342267; http://www.medicines.org.au/files/anpstemi.pdf |
| PubMed ID | US20080112953 |
| 3-D Structure | N.A. |